• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

DKA Knowledge Challenge!

News
Article

Diabetic ketoacidosis isn’t just an emergency room concern. It can start with subtle signs you might see first in your patients. This quick quiz zeroes in on the key red flags, risk factors, and management essentials of DKA that every PCP should know. Test your knowledge and sharpen your clinical instincts - it could make all the difference.

Click here to participate in survey

Related Videos
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Dapagliflozin slows decline of chronic kidney disease
Primary care physicians should prescribe SGLT2 inhibitors
Related Content
Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD / Image credit: ©Corona Borealis/AdobeStock

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

Sydney Jennings
September 2nd 2025
Article

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Sydney Jennings
August 28th 2025
Podcast

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial

Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial

Sydney Jennings
August 26th 2025
Article

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

FDA Clears First Over-The-Counter CGM for Weight Management From Signos / image credit ©lukszczepanski/stock.adobe.com

Signos Wins Clearance for First Over-The-Counter CGM for Weight Management

Grace Halsey
August 25th 2025
Article

The combination of the Dexcom Stelo glucose biosensor with an AI platform provides real-time data on how food, exercise, stress, and sleep affect the body.

In Adults With Obesity, GLP-1 Receptor Agonists May Reduce Risk for Certain Cancer / image credit Jian Bian, PhD, MS Courtesy of the Regenstrief Institute

In Adults With Obesity, GLP-1 Receptor Agonists May Reduce Risk for Cancer

Grace Halsey
August 22nd 2025
Article

GLP-1 use was associated with lower overall cancer risk, with the strongest associations observed for endometrial and ovarian cancers and meningioma.

© 2025 MJH Life Sciences

All rights reserved.